Photo taken from ASCO/X
Jun 15, 2024, 12:39
Docetaxel versus paclitaxel in black patients with breast cancer
The American Society of Clinical Oncology (ASCO) shared a post on X:
“ICYMI from ASCO24:
Although EAZ171 failed to meet its primary endpoint, Black patients with early-stage breast cancer who received docetaxel experienced less TIPN and fewer dose reductions than Black patients who received paclitaxel.”
Additional information.
Source: ASCO/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14